koto_feja/E+ via Getty Images
- Revvity (NYSE:RVTY) said on Wednesday that the U.S. FDA has approved its automated latent tuberculosis test.
- The Auto-Pure 2400 liquid handling platform with the T-SPOT TB test was initially launched outside the U.S. in 2024.
- RVTY stock up 0.5%.
